Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
Phase 2 Withdrawn
Chemo-embolization for Head and Neck Cancer
Phase 2 Withdrawn
HPV
Phase 2 Withdrawn
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Phase 2 Withdrawn
PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing
Phase 2 Withdrawn
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Phase 2 Withdrawn
Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
Phase 2 Withdrawn
ANAPLAST-NEO
Phase 2 Withdrawn
Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial
Phase 2 Withdrawn
Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer
Phase 2 Withdrawn
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Withdrawn
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
Phase 2 Withdrawn
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
Phase 2 Withdrawn
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Phase 2 Withdrawn
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
Phase 2 Withdrawn
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Withdrawn
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Phase 2 Withdrawn
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
Phase 2 Withdrawn
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Phase 2 Withdrawn
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Withdrawn
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
Phase 2 Withdrawn
RALT
Phase 2 Withdrawn
Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy
Phase 2 Withdrawn
ESMULLLAT
Phase 2 Withdrawn
DOME
Phase 2 Withdrawn
CECAVI
Phase 2 Withdrawn
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
Phase 2 Withdrawn
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
Phase 2 Withdrawn
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
Phase 2 Withdrawn
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
Phase 2 Withdrawn
HNSCC
Phase 2 Withdrawn
Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma
Phase 2 Withdrawn
IRAM
Phase 2 Withdrawn
Study Comparing AlloVax⢠to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
Phase 2 Withdrawn
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
Phase 2 Withdrawn
Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
Phase 2 Withdrawn
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
Phase 2 Withdrawn
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2 Withdrawn
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
Phase 2 Withdrawn
An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)
Phase 2 Withdrawn
Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer
Phase 2 Withdrawn
A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Withdrawn
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)
Phase 2 Withdrawn
Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies
Phase 2 Withdrawn
Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity
Phase 2 Withdrawn
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
Phase 2 Withdrawn
S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx
Phase 2 Withdrawn
PGx-SELECT
Phase 2 Withdrawn
Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer
Phase 2 Withdrawn
A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer
Phase 2 Withdrawn